News for Aquestive Therapeutics, Inc. (AQST)

Key Takeaways: Aquestive Therapeutics (AQST) surges nearly 5% in premarket trading following the FDA's acceptance of its New Drug Application for Anaphylm.

FDA assigns PDUFA target action date of January 31, 2026 WARREN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. ( AQST) (”œAquestive”

Discover why Aquestive Therapeutics' Anaphylm is set to revolutionize the $2B anaphylaxis market.

On June 2, 2025, analyst Andreas Argyrides from Oppenheimer has updated the rating for Aquestive Therapeutics (AQST). The firm has revised the price target from

Oppenheimer has initiated coverage on Aquestive Therapeutics (AQST) with an Outperform rating and a revised price target of $7, a decrease from the previous $15

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Aquestive Therapeutics (NASDAQ:AQST) was one of the stocks that was covered in that article. Wall Street analysts believe AQST has a 245% upside potential over the next 12 months. Aquestive Therapeutics, Inc. (NASDAQ:AQST) Upside Potential: 245.96% Aquestive Therapeutics (NASDAQ:AQST) stands out as […]

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Aquestive Therapeutics (NASDAQ:AQST) was one of the stocks that was covered in that article.

On May 15, 2025, Aquestive Therapeutics (AQST) has received a reaffirmation of its "Buy" rating from analyst Raghuram Selvaraju of HC Wainwright & Co. The analy

Total Revenue: Decreased to $8.7 million in Q1 2025 from $12.1 million in Q1 2024, a 28% decrease.Manufacturer and Supply Revenue: Decreased to $7.2 million in

May 13, 2025 / 12:00PM GMTOperator Good day, and thank you for standing by. Welcome to the Aquestive Therapeutics first quarter 2025 earnings conference call. (

Submitted NDA for Anaphylmâ„¢ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness

Aquestive Therapeutics (AQST) to participate in Piper Sandler Spring Biopharma Symposium on April 17, 2025. The company will conduct investor meetings d

Aquestive Therapeutics (AQST) stock gains as the company completes its marketing application for Anaphylm, an emergency treatment for allergic reactions. Read more here.

**media[582606,582607]**

Aquestive Therapeutics leverages its PharmFilm technology to develop innovative oral drug delivery systems. Find out why I'm neutral on AQST stock.

Release Date: March 06, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aquestive Thera

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAQST.OQ - Aquestive Therapeutics IncQ4 2024 Aquestive Therapeutics Inc Earnings CallMar 06, 20

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsBrian Korb - IRDan Barber - CEOErnie...

The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.